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ABSTRACT
Objective: The incidence, morbidity, and risk factors associated with Clostridium difficile-associated
diarrhea (CDAD) were studied in a group of gynecologic oncology patients.
Methods: A case-control analysis of gynecologic oncology patients with CDAD was carried out
from August 1986 through January 1989 in a university medical center.
Results: One hundred twenty-three stool samples were tested for C. difficile using the CDT latex
agglutination test (Marion Diagnostics, Kansas City, MO). Thirty episodes ofCDAD developed in
23 patients. From August 1986 through July 1988, the incidence was stable at 1.5 episodes/100
admissions. From August 1988 through January 1989, the incidence increased to 9.9 episodes/100
admissions (P 0.005). Compared with patients with nonspecific antibiotic-associated diarrhea, the
study patients were hospitalized longer prior to the development of symptoms (mean 15.2 vs. 9.2
days, P 0.006) and were admitted more frequently with diarrhea (37% vs. 11%, P 0.015). The
rates ofsurgery, chemotherapy, and radiation therapy were similar. Fever (57% vs. 14%,P < 0.001),
abdominal pain (40% vs. 6%, P < 0.001), bloody stools (27% vs. 3%, P 0.006), and leukocytosis
(64% vs. 26%, P 0.011) were more common among the study cases. The duration, indication, and
number of antibiotics administered were similar, though once started, the mean time to symptoms
was longer in the study cases (13.7 vs. 6.1 days, P 0.004). Seven relapses, 1 death, and 1 un-
planned colostomy occurred among women with CDAD.
Conclusions: C. difficile is a serious cause of nosocomial morbidity in gynecologic oncology
patients. Diarrhea developing after antibiotic exposure is more likely to be associated with C. difficile
in patients whose symptoms develop several days after completing antibiotics and in patients with a
history ofCDAD. (C) 1994 Wiley-Liss, Inc.
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lostridium difficile is the pathogen most often
responsible for nosocomially acquired diar-
rhea. Most cases occur in individuals with a his-
tory of recent antibiotic use, and the organism or its
toxins can be detected in the stool of 12-30% of
such individuals.
2-4 The clinical manifestations of
C. difficile-associated diarrhea (CDAD) are quite
variable, running a spectrum from mild, nuisance
diarrhea which resolves spontaneously to severe,
occasionally lethal infections characterized by
pseudomembranous colitis, toxic megacolon, or co-
Ionic perforation, s’6 Hospital-based epidemics are
well documented and reflect the frequent acquisi-
tion of the bacterium from other patients, staff, and
the hospital environment. 7’8
In addition to antibiotic use, the risk factors
implicated in the development of CDAD include
underlying malignancy, immunosuppression, in-
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TABLE I. Summary of data regarding patients and episodes of diarrhea
Cases Controls Total
Episodes of diarrhea identified 32 91 123
Number reviewed 32 60 92
Number excluded 2 24 26
Reasons for exclusion
No antibiotic exposure 0 3 3
Insufficient diarrhea 2 12 14
Diarrhea attributable to another cause 0 9 9
Episodes of diarrhea for analysis 30 36 66
Patients with a single episode of diarrhea 15 25 40
Patients with multiple episodes of diarrhea 6 6 12
All positive 6 6
All negative 4 4
Negative then positive 2 2
Age in years (mean and range) 61 (30-76) 59 (29-87)
Cancer present (%) 93 97
aTwo patients finishing treatment for CDAD who symptomatically improved.
bMainly includes stool samples collected for evaluation of fever without diarrhea being present.
cSix patients with radiation enteritis, 2 with short-bowel syndrome, and with an enterovaginal fistula.
creasing age, female gender, prolonged or recur-
rent hospitalizations, and exposure to chemother-
apy. 3’9-14 Most of these risk factors are present in
women with gynecologic malignancies. A descrip-
tion of the impact of this infection among this par-
ticular patient population has not been previously
reported, although several case-control studies on
different patient populations have compared indi-
viduals with CDAD with individuals without diar-
rhea 12’1s or with diarrhea not associated with anti-
biotic use.
3 Furthermore, several studies describing
the risks associated with antibiotic use have not
discussed antibiotic exposure prior to the hospital-
ization when CDAD was detected.
14-16 Other re-
ports, including those focusing on oncology pa-
tients, have been based on a relatively small number
of cases.
9,10,17,18
In early 1989, an increase in the incidence of
CDAD was observed among patients on a gyneco-
logic oncology service. This epidemic, which in-
cluded death from toxic megacolon, led to the
present case-control study on the impact of this
infection among these patients, particularly in com-
parison with the morbidity of nonspecific antibi-
otic-associated diarrhea.
SUBJECTS AND METHODS
A database in the hospital’s clinical laboratory was
surveyed to identify the results of all stool speci-
mens submitted for C. difficile analysis from pa-
tients hospitalized on the gynecologic oncology ser-
vice from August 1986 through January 1989 (123
stool samples collected from 106 patients). The
stool samples were collected primarily from pa-
tients with diarrhea and occasionally as part of a
fever evaluation. The latex agglutination test CDT
(Marion Diagnostics, Kansas City, MO) was used
throughout the study for the detection of C. diffi’-
cile. This assay detects a cell-wall antigen of C.
diffi’cile and is a more rapid and less expensive
alternative to tissue-culture-based cytotoxicity as-
19,20 says.
Thirty-two CDT-positive and 91 CDT-nega-
tive episodes of diarrhea were identified from the
laboratory reports (Table 1). Hospital and clinic
charts from all positive episodes were reviewed.
Two CDT-negative episodes for each CDT-posi-
tive episode were matched by month of testing and
also reviewed. The eligibility criteria for final anal-
ysis included a history of current or recent (within
8 weeks) antibiotic use and significant diarrhea (>3
liquid stools in 24 h) not attributable to another
cause. The incidence ofCDAD infection was calcu-
lated from the ratio of the number of episodes of
CDAD to the number of surgical and medically
related admissions to the gynecologic oncology ser-
vice over 6-month periods.
Statistical Analysis
The differences between means were analyzed with
the Student’s t-test. The differences in frequencies
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Fig. I. Prevalence of CDAD. Patients testing positive by
the CDT assay are represented by the shaded areas and
increased from 16% of total samples tested during the first
24 months of the study to 40% during the last 6 months
(P 0.0037).
were evaluated with the Fisher exact test. Two-
tailed tests were used for all comparisons.
RESULTS
Prevalence and Incidence
The stool samples were analyzed on 123 occasions
over the 30-month study, representing a stool anal-
ysis of 12.6% of patients admitted to the gyneco-
logic oncology service for surgery or medically
related problems. The CDT assay was positive in
32/123 (26%) instances (Fig. 1). If one considers
separately the periods from August 1986 through
July 1988 and August 1988 through January 1989,
the proportion of positive samples increased signif-
icantly from 12/73 (16%)instances to 20/50 (40%)
instances (P=0.0037). From August 1986
through July 1988, the 6-month incidence of
CDAD was stable at 1.5 cases/100 admissions.
From August 1988 through January 1989, the in-
cidence increased sharply to 9.9 cases/100 admis-
sions (P 0.005, Fig. 2). No episodes ofdiarrhea
were felt to be secondary to parasitic or other bacte-
rial infections during the course of the study.
Risk Factors (Table 2)
A similar proportion of the cases and the compari-
son group had been hospitalized in the 8 weeks
preceding diarrhea; however, patients with CDAD
spent a significantly greater number of days in the
hospital over the 8 weeks prior to the onset of
symptoms (P 0.006). The cases were more com-
monly admitted with diarrhea as a chief complaint
(P 0.015), and each episode of CDAD which
began at home had been preceded by or more
hospitalizations within the prior 8 weeks. Patients
with CDAD were much less likely to have been
admitted for a scheduled surgical procedure during
the hospitalization when the diarrhea developed
(P 0.002). The relationship between surgery and
the risk of CDAD was less significant (P 0.06)
if any surgical procedure in the 8 weeks preceding
symptoms was considered. Exposure to chemother-
apy in the 8 weeks preceding diarrhea as well as
current or previous radiotherapy to the abdomen or
pelvis was similar in the 2 groups.
Morbidity (Table 3)
In comparison with patients with nonspecific diar-
rhea, the mean duration of diarrhea was signifi-
cantly greater in patients with CDAD, as was the
likelihood of fever, abdominal pain, and bloody
stool (P < 0.01 for each symptom). When checked
within 24 h of the CDT assay (cases, 25 instances;
comparison groups, 23 instances), the mean white
blood cell (WBC) count was significantly higher
among patients with CDAD (P 0.018). Among
the cases, there was death due to toxic megacolon
and patient required a colostomy for persistent
lower intestinal bleeding secondary to pseudomem-
branous colitis.
Antibiotic Profiles
Each patient received or more courses of antibiot-
ics in the 8 weeks preceding the onset of diarrhea.
CDAD developed after exposure to a single antibi-
otic in 7 instances and after a single dose in 2 cases.
The cumulative number of days of exposure to
antibiotics over the 8 weeks preceding the onset of
diarrhea did not differ significantly between the 2
groups (12.7 ---
11.8 vs. 12.0 ---
10.6 days,
P 0.82). The average total number of different
antibiotics given was also similar (2.2 ---
1.5 vs.
2.5 ---
1.5, P 0.36). The cases, however, more
commonly received their most recent course of an-
tibiotics prior to the hospitalization when the stool
sample was sent for C. difficile analysis (19/30,
63% vs. 5/36, 14%, P < 0.001). Correspond-
ingly, patients with nonspecific diarrhea were more
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Incidence ofCDAD on the gynecologic oncology service from August 1986 through January
TABLE 2. Risk factors in the development of CDAC
Cases (N 30) Controls (N 36)
Hospitalized within 8 weeks of symptoms (%)
Days hospitalized prior to symptoms (mean +- SD)
Admitted with diarrhea (%)
Admitted for surgery (%)
Surgery in the prior 8 weeks (%)
Recent chemotherapy (%)
Prior or current radiation therapy (%)
60 45 0.21
15.2 +- 10.7 9.2 _+ 5.2 0.006
36 II 0.015
30 78 0.002
57 78 0.06
47 33 0.27
37 26 0.10
TABLE 3. Morbidity associated with diarrhea
Cases (N 30) Controls (N 36)
Days of diarrhea (mean +- SD) 9.8 _+ 6.3 2.1 -+ 1.7 <0.001
Abdominal pain (%) 40 6 <0.001
Bloody stool (%) 27 3 0.006
Fever >38.5C (%) 57 14 <0.001
WBC ( 109/1, mean +- SD) 14.7 _+ 8.0 10.0 _+ 4.8 0.018
aA patient’s complaint or clinician’s assessment of abdominal cramps, pain, or tenderness.
bGross or occult evidence of blood in the stool.
likely to develop diarrhea while taking antibiotics
or within 3 days of finishing antibiotics (26/36,
73% vs. 14/30, 47%, P 0.036).
In 14- CDAD and 25 nonspecific episodes of
diarrhea, a single course of antibiotics preceded the
onset of symptoms (Table 4). For these patients,
the number of different antibiotics given, total days
of exposure, and indications for use were similar.
The time interval from the onset of antibiotic expo-
sure to the onset ofsymptoms differed significantly,
however. Among patients with CDAD, the symp-
toms began an average of 13.7 days after receiving
antibiotics in comparison with 6.1 days among the
comparison group with nonspecific diarrhea
(P 0.004).
No antibiotic class was used with significantly
greater frequency in the patients with CDAD com-
pared with the comparison group, but exposure to
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TABLE 4. Episodes of diarrhea preceded by a single antibiotic regimen
Cases (N 14) Controls (N 25) P
Total days of antibiotic exposure (mean +- SD) 7.8 +- 6.7 7.2 -+ 6.5 0.77
Number of antibiotics (mean -+ SD) 1.9 -+ 1.2 2.3 +- 1.3 0.35
Days from onset of antibiotics to onset of symptoms 13.7 -+ 8.6 6. _+ 2.9 0.004
(mean -+ SD)
Indications for antibiotic use (%)
Prophylactic 50 40 0.39
Empiric 28 44 0.27
Therapeutic 21 16 0.23
Specific antibiotic use (%)
Cephalosporin 86 72 0.28
Penicillin 21 36 0.28
Metronidazole 14 4 0.29
Oral erythromycin-neomycin 7 20 0.28
Azactam 14 16 0.64
Imipenam 7 0 0.36
Clindamycin 0 12 0.25
Aminoglycoside 7 40 0.030
Patients with recurrent diarrhea 12
First episode CDAD 6 yes 6 no
Next episode CDAD 6 yes 2 yes 4 no
Fig. 3. Influence of a prior episode ofCDAD on recurrent
diarrhea. Risk of recurrence with CDAD was highly associ-
ated (P 0.030) with a history of CDAD.
aminoglycosides was significantly more common in
patients without CDAD (P 0.030).
Relapses
Twelve patients had more than episode of diar-
rhea. Six had a history of CDAD; in each case, the
recurrent diarrhea, 7 total episodes, was C. difficile
positive. These patients represented 26% of the
individuals who developed CDAD and accounted
for 43% of the total episodes of CDAD. Six pa-
tients had a history of nonspecific diarrhea. Two of
these individuals subsequently developed a single
episode of CDAD, and the 4 other patients had 5
recurrent episodes of nonspecific diarrhea. Thus, a
prior episode of CDAD was a significant risk fac-
tor in predicting whether recurrent diarrhea was
also due to C. difficile (P 0. 030, Fig. 3).
Therapy
The therapy for CDAD included starting oral met-
ronidazole or vancomycin and discontinuing other
antibiotics if feasible. On the rare occasion that oral
medication was not possible, IV metronidazole or
vancomycin enemas were given. Medications con-
tributing to bowel stasis were stopped, and fluid
and electrolyte disturbances corrected. The dura-
tion of diarrhea, once the therapy had been started,
averaged 4.8 days (range 1-18 days). Three of 7
relapses developed after initial treatment with met-
ronidazole and 4 after vancomycin. All relapses
responded to or more additional courses of vanco-
mycin.
DISCUSSION
This study examines the risk factors, morbidity,
antibiotic profiles, treatment response, and inci-
dence ofCDAD on a gynecologic oncology service.
The cases and the comparison group were of the
same sex, from the same ward, of similar age, and
with a similar incidence of cancer. A single C.
difficile assay was used throughout the study.
Risk Factors
The most severe cases of antibiotic-associated diar-
rhea involve C. difficile, and toxin-producing C.
difficile is rarely ever detected without a history of
antibiotic use. 2’a2 All of our cases had received
or more antibiotics within 8 weeks prior to the
onset of symptoms, which supports the general be-
lief that antibiotic use is the major risk factor in the
etiology of CDAD.
C. difficile infections may occur as an epidemic
in the hospital, and nosocomial transmission has
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been well described. 7’8’23 In the present series, a
similar proportion of patients with CDAD and non-
specific diarrhea had been admitted to the hospital
during the 8 weeks prior to the hospitalization when
a stool sample was tested for C. diffi’cile. Patients
with CDAD, however, averaged more days in the
hospital (mean 15.2 vs. 9.2 days, P 0.006)
which may reflect a greater opportunity of acquir-
ing C. diffi’cile from other patients, staff, or the
hospital environment. The dramatic increase in the
incidence of CDAD beginning in August 1988
lasted about 6 months before returning to baseline
levels. The resolution of this epidemic coincided
with an increased focus on the importance of hand-
washing and isolation of infected individuals.
Chemotherapeutic agents are occasionally con-
sidered risk factors in the development of
CDAD,
13,24 though concurrent exposure to antibi-
otics is not uncommon.
2s In our study, all patients
receiving chemotherapy who developed CDAD had
also received or more antibiotics during the same
time period. Overall, 40% of the episodes of diar-
rhea in the study were preceded by chemotherapy
in the previous 8 weeks, and no significant differ-
ence was noted between cases and the comparison
group.
Radiation therapy was considered as possibly con-
tributing to the risk ofCDAD. Radiotherapy to the
pelvis or abdomen often results in diarrhea during
and after treatment. Antimotility agents, commonly
used to control diarrhea, may increase the incidence
of antibiotic-associated diarrhea and worsen its se-
verity in established cases.
26 Forty-seven percent of
cases and 3 3% of patients with nonspecific diarrhea
had received radiotherapy to the abdomen or pel-
vis, an incidence not significantly different, there-
fore suggesting that radiation therapy was not an
independent risk factor in our patient population.
Gastrointestinal surgery has been considered by
some to be a risk factor for CDAD, 14’27 while
others
2s have noted no apparent increase in CDAD
after abdominal surgery in comparison with other
surgical procedures. Controlling for horizontal
transmission also reduces the apparent risk from
surgery.
6 In our series, the cases were signifi-
cantly less likely to have had surgery during the
admission when stool samples were analyzed for C.
difficile. This observation is biased by the greater
likelihood of admission for medical problems, in-
cluding diarrhea, among patients with CDAD when
compared with patients with nonspecific diarrhea.
As interactions between surgery and antibiotic ex-
posure may occur several weeks prior to symptoms,
a more appropriate analysis of the risk of surgery
would compare the rates of surgery over the previ-
ous several weeks. When examined in this context,
the percentage of cases having had surgery in the
prior 8 weeks more closely approximates the inci-
dence in the comparison group. In the present
study, surgery to the small or large intestines was
associated with CDAD diarrhea in 6 instances.
Nonspecific diarrhea developed in 8 patients, which
suggests that gastrointestinal surgery alone was not
an independent risk factor in our patient popula-
tion.
Morbidity
Patients with CDAD can become quite ill and sev-
eral series have described the morbidity associated
with this illness. 12’2s’28’29 Among cases in the
present series, there was death due to toxic mega-
colon and unplanned colostomy for persistent
colonic bleeding from pseudomembranous colitis.
Additional morbidity among the patients with
CDAD included fever (57%), abdominal pain or
cramps (40%), bloody stool (27%), and leukocyto-
sis (64%). These features were unusual in the com-
parison group. The duration of diarrhea, another
manifestation of morbidity, was longer in the pa-
tients with CDAD. In 11 (37%) instances, patients
treated with antibiotics were readmitted to the hos-
pital with diarrhea or abdominal pain as a chief
complaint and found to have C. diffi’cile. One hun-
dred eight patient-days were spent in the hospital as
a result of this nosocomially acquired infection. In
contrast, only 4 women with nonspecific diarrhea
were admitted with diarrhea as a presenting com-
plaint, and in no instance was diarrhea the primary
complaint.
Antibiotic Profiles
The duration and number of antibiotics have been
considered by some to increase the risk of develop-
ing CDAD, 4’ 15 while others have not confirmed
this.’2 Among our patients, there was no differ-
ence between cases and the comparison group in the
duration of antibiotic exposure or average number
of antibiotics used. Unlike several previous stud-
ies,
4-6 our series considered exposure to all anti-
biotics in the 8 weeks preceding symptoms. Many
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patients received several antibiotic regimens prior
to developing diarrhea, making it difficult to iden-
tify a responsible agent. In the group of patients
who had received only a single drug or regimen,
we were unable to identify any antibiotic used with
significantly greater frequency among the women
with CDAD. Aminoglycosides, usually gentami-
cin, were used more commonly in the comparison
group. These agents do not have an enterohepatic
circulation and so do not cause significant changes
in bowel flora. It is unclear if this feature contrib-
uted to the decreased frequency of CDAD among
our subjects, as all patients receiving an aminogly-
coside concurrently received a cephalosporin or pen-
icillin.
The symptoms ofCDAD typically develop after
several days of antibiotic therapy, though they may
occur as early as the first or second day or as late as
several weeks after discontinuation of antibiotics.
3
Among subjects with CDAD, the onset of symp-
toms ranged from 4 to 3 5 days after initiation of
antibiotics and averaged 13.7 days. Diarrhea in the
comparison group usually started during or shortly
after completing antibiotics. In a prior study of 151
patients with CDAD,
25 67 (44%) had discontinued
antibiotics >21 days prior to the onset of symp-
toms. Symptoms began in 56% of the patients after
discharge from the hospital. In our series, 37% of
cases developed symptoms after discharge from the
hospital.
in the development of this infection. Individuals
with a history of CDAD who again develop diar-
rhea are likely to be infected with C. diffi’cile, and
empiric therapy with metronidazole or vancomycin
should be considered while the cause of the diarrhea
is being determined. In addition, patients whose
symptoms develop several days after completion of
antibiotic therapy are at much higher risk of having
CDAD than nonspecific diarrhea. Among patients
who develop diarrhea while receiving antibiotics,
sufficient overlap exists between those with and
without C. difficile to make this factor clinically
unreliable, though individuals with CDAD often
appear more ill and suffer from worse diarrhea
than individuals without C. difficile.
Antibiotic use is likely to maintain its signifi-
cance in the medical and surgical treatment of on-
cology patients. A recognition of the potentially
serious consequences of CDAD, including its ten-
dency for horizontal transmission, is important.
Enteric infection control procedures including iso-
lation of infected patients and frequent hand wash-
ing are additional important measures which should
be taken to minimize the development and spread
of this nosocomial infection.
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Treatment Response
The response of CDAD to therapy, either with
metronidazole or vancomycin, was good. Most pa-
tients with severe illness were treated initially with
vancomycin, as has been recommended. Relapse
occurred in 6/23 different patients with CDAD, a
frequency consistent with the experience of oth-
10 17,25,32 ers. Failure of initial therapy was equally
likely after metronidazole or vancomycin. In a prior
study, patients with CDAD who relapsed were of a
greater age and had a higher frequency of recent
abdominal surgery in comparison with patients who
did not relapse.
3 No such differences were noted
in the present series.
CONCLUSIONS
CDAD is an important source of nosocomially ac-
quired morbidity in gynecologic oncology patients.
Antibiotic therapy remains the primary risk factor
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